Setting | tOPV serotype | bOPV serotype | ||||
---|---|---|---|---|---|---|
 | 1 | 2 | 3 | 1 | 2 | 3 |
Clinical trials | ||||||
Central and Southern India [25], 2 doses at 0 and 30Â days of age | 0.39 | 0.70 | 0.31 | 0.62 | 0.06 | 0.49 |
Bangladesh [26], 3-doses at 6, 10, and 14Â weeks of age) | 0.57 | 0.65 | 0.51 | 0.70 | 0.06 | 0.65 |
0.45 | 0.70 | 0.35 | 0.54 | 0 | 0.54 | |
0.35 | 0.60 | 0.27 | 0.42 | 0 | 0.42 | |
Global model assumptions based on calibrated DEB model [20] | ||||||
Lowest tier (e.g., Northern India) | 0.35 | 0.60 | 0.27 | 0.42 | 0 | 0.42 |
Second tier (e.g., Northern Pakistan) | 0.40 | 0.65 | 0.32 | 0.50 | 0 | 0.50 |
Third tier (e.g., Northwest Nigeria) | 0.45 | 0.70 | 0.35 | 0.54 | 0 | 0.54 |
Fourth tier (e.g., Brazil) | 0.50 | 0.72 | 0.40 | 0.60 | 0 | 0.60 |
Fifth tier (e.g., Philippines, Turkey) | 0.55 | 0.73 | 0.45 | 0.70 | 0 | 0.70 |
Sixth tier (e.g., Russia, middle-income China) | 0.60 | 0.74 | 0.50 | 0.75 | 0 | 0.75 |
Seventh tier (e.g., upper-income China, Israel) | 0.65 | 0.75 | 0.55 | 0.80 | 0 | 0.80 |